- Home
- KPRX vs PAVM Comparison
KPRX vs PAVM Comparison
Compare KPRX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- PAVM
- Stock Information
- Founded
- KPRX 1998
- PAVM 2014
- Country
- KPRX United States
- PAVM United States
- Employees
- KPRX N/A
- PAVM N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PAVM Medical/Dental Instruments
- Sector
- KPRX Health Care
- PAVM Health Care
- Exchange
- KPRX Nasdaq
- PAVM Nasdaq
- Market Cap
- KPRX 9.2M
- PAVM 9.7M
- IPO Year
- KPRX N/A
- PAVM 2016
- Fundamental
- Price
- KPRX $2.75
- PAVM $0.49
- Analyst Decision
- KPRX Strong Buy
- PAVM Strong Buy
- Analyst Count
- KPRX 1
- PAVM 1
- Target Price
- KPRX $10.00
- PAVM $20.00
- AVG Volume (30 Days)
- KPRX 35.6K
- PAVM 223.3K
- Earning Date
- KPRX 11-07-2025
- PAVM 11-12-2025
- Dividend Yield
- KPRX N/A
- PAVM N/A
- EPS Growth
- KPRX N/A
- PAVM N/A
- EPS
- KPRX N/A
- PAVM 0.83
- Revenue
- KPRX N/A
- PAVM $1,020,000.00
- Revenue This Year
- KPRX N/A
- PAVM N/A
- Revenue Next Year
- KPRX N/A
- PAVM $234.47
- P/E Ratio
- KPRX N/A
- PAVM $0.58
- Revenue Growth
- KPRX N/A
- PAVM N/A
- 52 Week Low
- KPRX $2.25
- PAVM $0.30
- 52 Week High
- KPRX $4.18
- PAVM $1.29
- Technical
- Relative Strength Index (RSI)
- KPRX 55.26
- PAVM 63.59
- Support Level
- KPRX $2.67
- PAVM $0.44
- Resistance Level
- KPRX $2.89
- PAVM $0.47
- Average True Range (ATR)
- KPRX 0.11
- PAVM 0.03
- MACD
- KPRX 0.02
- PAVM 0.01
- Stochastic Oscillator
- KPRX 70.26
- PAVM 71.59
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.